{"result": "(\"entity\"<|>QUEBEC<|>GEO<|>Quebec is a province in Canada where a 20-year retrospective population-based study on congenital hypothyroidism was conducted.)\n##\n(\"entity\"<|>J CLIN ENDOCRINOL METAB<|>ORGANIZATION<|>J Clin Endocrinol Metab is a medical journal that published studies related to endocrinology, including those on congenital hypothyroidism.)\n##\n(\"entity\"<|>EUROPEAN SOCIETY FOR PAEDIATRIC ENDOCRINOLOGY<|>ORGANIZATION<|>The European Society for Paediatric Endocrinology provides consensus guidelines for screening, diagnosis, and treatment of congenital hypothyroidism.)\n##\n(\"entity\"<|>REV ESP ENDOCRINOL PEDIATR<|>ORGANIZATION<|>Rev Esp Endocrinol Pediatr is a Spanish journal that discusses neonatal screening in endocrine diseases.)\n##\n(\"entity\"<|>LITIO<|>PERSON<|>Lithium is a medication known to cause primary hypothyroidism in some patients.)\n##\n(\"entity\"<|>AMIODARONA<|>PERSON<|>Amiodarone is a drug that can cause both hyperthyroidism and hypothyroidism, particularly in patients with pre-existing thyroid conditions.)\n##\n(\"entity\"<|>INTERFERÓN α<|>PERSON<|>Interferon alpha is a medication that can alter thyroid function, potentially leading to both hyperthyroidism and hypothyroidism.)\n##\n(\"entity\"<|>HIPOTIROIDISMO PRIMARIO<|>EVENT<|>Primary hypothyroidism is a condition characterized by insufficient thyroid hormone production, leading to various metabolic issues.)\n##\n(\"relationship\"<|>QUEBEC<|>J CLIN ENDOCRINOL METAB<|>The study on the incidence of congenital hypothyroidism was published in the J Clin Endocrinol Metab journal, which is relevant to Quebec's research<|>7)\n##\n(\"relationship\"<|>EUROPEAN SOCIETY FOR PAEDIATRIC ENDOCRINOLOGY<|>REV ESP ENDOCRINOL PEDIATR<|>Both organizations provide guidelines and research related to pediatric endocrinology, including congenital hypothyroidism<|>6)\n##\n(\"relationship\"<|>LITIO<|>HIPOTIROIDISMO PRIMARIO<|>Lithium is known to cause primary hypothyroidism in a significant percentage of patients<|>8)\n##\n(\"relationship\"<|>AMIODARONA<|>HIPOTIROIDISMO PRIMARIO<|>Amiodarone can lead to primary hypothyroidism, especially in patients with Hashimoto's thyroiditis<|>8)\n##\n(\"relationship\"<|>INTERFERÓN α<|>HIPOTIROIDISMO PRIMARIO<|>Interferon alpha can cause alterations in thyroid function, leading to primary hypothyroidism<|>8)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: , la incidencia de hipotiroidismo congénito se cifra en 1 de cada 1.850 recién nacidos. Parece existir un discreto aumento en los últimos años, probablemente debido a modificaciones en el umbral de TSH para realizar estudios confirmatorios. Por estos motivos, la primera opción se puede considerar cierta.\n\nLa principal causa de hipotiroidismo congénito es la disgenesia tiroidea, que explica el 85% de los casos (opción D falsa). La segunda causa más frecuente son los defectos en la síntesis de hormonas tiroideas, que explican entre el 10% y el 15% de los casos (opción B).\n\nUna de las causas de hipotiroidismo congénito es la transferencia materna de anticuerpos bloqueantes del receptor de la TSH, aunque en este caso el hipotiroidismo es transitorio (opción C).\n\nReferencias:\n- Deladoey J, Ruel J, Giguere Y, Van Vliet G. Is the incidence of congenital hypothyroidism really increasing? A 20-year retrospective population-based study in Quebec. J Clin Endocrinol Metab. 2011;96:2422-9.\n- LaFranchi SH. Approach to the diagnosis and treatment of neonatal hypothyroidism. J Clin Endocrinol Metab. 2011;96:2959-67.\n- Leger J, Olivieri A, Donaldson M. European Society for Paediatric Endocrinology Consensus Guidelines of screening, diagnosis and treatment of congenital hypothyroidism. Horm Res Pediatr. 2014;81:80-103.\n- Rodríguez A, Sanz M, Dulin E, Rodríguez-Arnao MD. Cribado neonatal en enfermedades endocrinológicas. Rev Esp Endocrinol Pediatr. 2017;8(Suppl):47-61.\n\n### 2. ¿Cuál de los fármacos siguientes no produce un hipotiroidismo primario?\n\nA. Litio.\nB. Amiodarona.\nC. Interferón α.\nD. Todas las respuestas son ciertas.\n\nCOMENTARIO\n\nLos tres fármacos son causas bien conocidas de hipotiroidismo primario (opción D correcta).\n\nEl litio causa hipotiroidismo hasta en un 20% de los pacientes tratados con este fármaco. El mecanismo por el que inhibe la síntesis de hormonas tiroideas es múltiple. Por una parte, inhibe la captación tiroidea de yodo, pero también interfiere en el acoplamiento de las yodotirosinas, altera la estructura de la tiroglobulina e inhibe la secreción de las hormonas tiroideas por el tirocito.\n\nLa amiodarona puede causar tanto hipertiroidismo como hipotiroidismo. El hipotiroidismo habitualmente se desarrolla en pacientes con una tiroiditis de Hashimoto previa y se considera que es debido a que el tiroides de estos pacientes presenta una susceptibilidad aumentada al efecto Wolff-Chaikoff, de forma que es incapaz de escapar al efecto inhibitorio del yodo sobre la síntesis de hormonas tiroideas.\n\nIgualmente, el interferón puede causar alteración de la función tiroidea (tanto hipertiroidismo como hipotiroidismo) por sus efectos inmunomoduladores.\n\nReferencias:\n- Barbesino G. Drugs affecting thyroid function. Thyroid. 2010;20:763-70.\n- Kibirige D, Luzinda K, Ssekitoleko R. Spectrum of lithium induced thyroid abnormalities: a current perspective. Thyroid Res. 2013;6:3.\n- Lazarus JH. Lithium and Thyroid. Best Pract Res Clin Endocrinol Metab. 2009;23:723-33.\n- Martino E, Bartalena L, Bogazzi F, Braverman LE. The Effects of Amiodarone on the Thyroid. Endocrine Rev. 2001;22:240-54.\n- Tomer Y, Blackard JT, Akeno N. Interferon alpha treatment and thyroid dysfunction. Endocrinol Metabol Clin North Am. 2007;36:1051-66.\n\n### 3. Indique cuál de las siguientes opciones es cierta en el hipotiroidismo primario:\n\nA. Los transportadores de glucosa sensibles a insulina (GLUT-4) están aumentados.\nB. El balance de nitrógeno es negativo.\nC. El hipotiroidismo condiciona tanto la elevación de colesterol como de triglicéridos.\nD. La respuesta adrenérgica está aumentada y el input simpático está disminuido.\n\nCOMENTARIO\n\nLas hormonas tiroideas aumentan la expresión del transportador de glucosa sensible a insulina (GLUT 4), y se han comprobado niveles reducidos de este transportador en el hipotiroidismo (opción A falsa).\n\nTanto la síntesis como la degradación de las proteínas están reducidas en el hipotiroidismo. Sin embargo, la degradación está disminuida en mayor grado, por lo que habitualmente se produce en el hipotiroidismo un balance nitrogenado ligeramente positivo (opción B falsa).\n\nAl\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}